Advertisement
News
Advertisement

Novartis halts lung cancer trial

Thu, 11/11/2010 - 9:35am
Mass High Tech: The Journal of New England Technology

Novartis AG said it is discontinuing late stage clinical trials for a drug candidate to treat lung cancer because the trial was unlikely to meet its endpoint.

Trials on the investigational cancer drug, called ASA404, will be terminated, resulting in a $120 million charge to the company, according to a Novartis press release. Switzerland-based Novartis, which houses its Institutes for Biomedical Research headquarters in Cambridge, said it would shift its focus to its other potential cancer treatments.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading